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a b s t r a c t
Transformation from indolent non-Hodgkin lymphoma (NHL) to diffuse large B cell lymphoma (DLBCL) has
historically been associated with a poor prognosis. A small series of autologous stem cell transplantation (ASCT)
studies using conventional conditioning regimens has demonstrated durable progression-free survival (PFS)
rates ranging from 25% to 47%, but data in the rituximab era are lacking. Here we report the results of a multi-
center retrospective trial evaluating ASCT in patients with transformed lymphoma using the Z-BEAM condi-
tioning regimen, which combines yttrium-90elabeled ibritumomab tiuxetan (Zevalin) with high-dose BEAM
(carmustine, etoposide, cytarabine, melphalan) chemotherapy. Sixty-three patients from 4 institutions were
treated between 2003 and 2011. Histological conﬁrmation of transformation was required and deﬁned as a
diagnosis of DLBCL in patients with either a prior history or concomitant diagnosis of low-grade B cell NHL.
Median patient age at ASCT was 59.5 years, median number of prior regimens was 2, and all patients were
exposed to rituximab. Disease status at ASCT was as follows: ﬁrst complete remission (CR) (n ¼ 30), ﬁrst partial
remission (n ¼ 11), ﬁrst relapse (n ¼ 14), and at least second CR (n ¼ 8). The median time from diagnosis of
histological transformation to ASCT was 7.5 months (range, 2.8 to 116). Two-year nonrelapse mortality was 0%.
Median follow-up for living patients was 28 months (range, 5 to 103). Two-year PFS was 68% (95% conﬁdence
interval, 58% to 75%), and overall survival was 90% (95% conﬁdence interval, 80% to 95%). In conclusion, the
Z-BEAM conditioning regimen for ASCT is well tolerated by patients with transformed lymphoma and dem-
onstrates encouraging clinical outcomes.
 2014 American Society for Blood and Marrow Transplantation.
INTRODUCTION
The low-grade B cell lymphomas are a collective group of
diseases with an indolent natural history. Although long re-
missions with therapy are very common, relapses tend to be
the rule rather than the exception, and transformation to a
higher grade lymphoma can occur at a rate of approximately
3% per year in the case of follicular lymphoma [1] and
perhaps as high as 16% in the case of nonemucosa-associated
lymphoid tissue marginal zone lymphoma [2]. Although
most data in the literature revolve around the transformation
of follicular lymphoma into diffuse large B cell lymphoma,
other indolent B cell lymphomas, such as small lymphocytic
lymphoma and marginal zone lymphoma, are also known to
transform into higher grade disease. Historically, long-term
outcomes after transformation have been poor, with 1
study showing a median survival after transformation of
1.2 years [3]. However, survival has improved signiﬁcantly in
the rituximab era [4].
Autologous stem cell transplantation (ASCT) is a treat-
ment modality used to overcome the poor prognosis asso-
ciated with transformed lymphoma. A number of small
series consistently show that many patients with trans-
formed lymphoma who undergo ASCT can enjoy prolonged
remissions [5-7]. One of the few prospective trials evaluating
the outcomes of ASCT in transformed lymphoma demon-
strates a median progression-free survival (PFS) and overall
survival (OS) of 26 months and 47 months, respectively, with
2-year and 5-year OS of 73% and 47%, respectively [8].
Whether these results are applicable in the context of prior
rituximab is not clear; however, a limited but growing body
of literature suggests that overall clinical outcomes in the
rituximab era are also signiﬁcantly improved by ASCT com-
pared with historical controls, with 2-year survival exceed-
ing 80% [9,10].
Despite the positive trend in overall outcomes with rit-
uximab, the major cause of mortality in this population
remains disease progression, and improvement in available
therapies is still needed. One potential avenue is modiﬁcation
of the ASCT conditioning regimen. The addition of the radio-
labeled antibody yttrium-90 ibritumomab tiuxetan (Zevalin)
to the high-dose BEAM (carmustine, etoposide, cytarabine,
melphalan) chemotherapy regimen (Z-BEAM) has been
shown to have a similar toxicity proﬁle as BEAM alone in
historical control patients with relapsed/refractory non-
Hodgkin lymphoma (NHL) [11]. This regimen has also been
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evaluated in a small prospective randomized trial in relapsed/
refractory aggressiveNHLpatients, which conﬁrmed its safety
and showed a trend toward improved outcomes [12]. Given
these promising results, we present the outcomes of trans-
formed lymphoma treated with ASCT conditioned with Z-
BEAM in a retrospectives series of patients from 4 institutions
(City of Hope, VU University Medical Center, Chaim Sheba
Medical Center, and University Medical Center Göttingen).
METHODS
Physicians at the selected institutions received a standardized electronic
spreadsheet specifying the required data ﬁelds. After local institutional re-
view board clearance, researchers retrospectively reviewed institutional
databases for patients meeting the speciﬁed eligibility criteria.
Major eligibility included a diagnosis of transformed NHL, with histo-
logical diagnosis conﬁrmed at the treating institution. Transformed NHL
was deﬁned as initial biopsy-proven indolent lymphoma with subsequent
occurrence of biopsy-proven diffuse large B cell lymphoma (DLBCL). The
initial indolent subtypes included grades 1 and 2 follicular lymphoma,
marginal zone lymphoma, and mucosa-associated lymphoid tissue lym-
phoma. All patients were treated with at least 1 rituximab-containing
regimen after transformation and before ASCT. Data on patient characteris-
tics at the time of transformation, such as extent of disease, stage, and lactate
dehydrogenase, were not available for many patients because initial treat-
ment was often delivered by community hospitals, with patients referred to
the participating transplant centers only after transformation. Patients were
older than 18 years of age, had less than 25%marrow involvement at time of
stem cell collection, and passed the institutional standard organ function
criteria for ASCT. Patients were eligible if they achieved a partial remission
(PR) or complete remission (CR)with conventional chemoimmunotherapy at
either initial treatment or salvage therapy before ASCT.
Stem cell collection was performed with either granulocyte colony-
stimulating factor or chemomobilization, and Z-BEAM conditioning was
administered as previously described [11,12]. Post-transplant transfusional
support and infectious prophylaxis was as per institutional standard prac-
tice. Neutrophil and platelet engraftment were deﬁned as the ﬁrst of 3 days
with an absolute neutrophil count >.5  109/L and the ﬁrst 7 days with an
untransfused platelet count >20  109/L. Toxicity post-ASCT was graded by
the Bearman et al. toxicity criteria [13]. Disease response criteria were from
the 1999 International Working Group [14]. CR was deﬁned as the complete
resolution of all measurable disease, sustained for at least 4 weeks. PR was
deﬁned as a 50% or more reduction in the sum of the products of the
diameters of all measurable lesions. Relapse was deﬁned as a clinical or
radiological progression at least 4 weeks after an initial CR or PR to ﬁrst-line
therapy. Response was evaluated approximately every 3 months post-ASCT
for the ﬁrst 2 years and then every 3 to 6 months or as clinically indicated.
Statistical Methods
The primary outcome of the study was progression-free survival (PFS),
deﬁned as the time from ASCT to date of disease relapse, progression, or
death from any cause, whichever occurred ﬁrst. Other outcomes examined
included overall survival (OS), measured from the day of ASCT until death
from any cause, and nonrelapse mortality (NRM), measured from transplant
to death from any cause other than disease relapse or disease progression.
Survival estimates were calculated based on the Kaplan-Meier product-limit
method, and 95% conﬁdence intervals (CIs) were calculated using the logit
transformation and the Greenwood variance estimate. Differences between
Kaplan-Meier curves were assessed by the log-rank test. Patients who were
alive at the time of analysis were censored at the last contact date.
The signiﬁcance of demographic and treatment features was assessed
using stratiﬁed survival analysis and univariate, multivariable Cox propor-
tional hazards regression analysis or the corresponding hazard analysis for
competing risks. Univariate analysis was performed to evaluate the signiﬁ-
cance of the following factors: sex (female, male), age at the time of ASCT
(<59.5, 59.5), time from diagnosis of transformation to ASCT (<7.5, 7.5),
disease status at ASCT (1 CR, >1 CR), number of prior regimens (2, >2),
presence of marrow involvement at the time of ASCT (yes, no), and center
(City of Hope, VU University Medical Center, Chaim Sheba Medical Center,
and University Medical Center Göttingen). All calculations were performed
using SAS version 9.2 (SAS Institute, Cary, NC). Generally, statistical signiﬁ-
cance was set at the P < .05 level; all P values were 2-sided. The data were
locked for analysis on March 4, 2013 (analytic date).
RESULTS
Sixty-three patients (24 women and 39 men) who un-
derwent ASCT between 2003 and 2011 were enrolled from 4
centers. Patient characteristics are listed in Table 1. Median
age at ASCT was 59.5 years (range, 36 to 69). The median
time from transformation to ASCT was 7.5 months (range, 2.8
to 116). Before ASCT, patients received a median of 2 regi-
mens of chemotherapy (range, 1 to 6), and all had received
rituximab with at least 1 of these regimens. The distribution
of disease status at ASCTwas as follows: ﬁrst CR (n¼ 30), ﬁrst
PR (n ¼ 11), ﬁrst relapse (n ¼ 14), and beyond second CR
(n¼ 8). Disease stage at ASCTwas II to IV in 35 patients (56%),
and lactate dehydrogenase was above the upper range of
normal in 20 patients (32%).
All patients demonstrated WBC engraftment at a median
of 11 days (range, 8 to 33) after stem cell infusion. The me-
dian time to platelet engraftment was 15 days (range, 3 to
71). Of the 63 patients, 21 relapsed and 9 patients died.
Median duration of follow-up was 31.3 months (range, 7.1 to
103.4) for surviving patients, and the 2-year PFS was 68%
(95% CI, 58% to 75%) and 2-year OS 90% (95% CI, 80% to 95%).
On univariate analysis, only disease status at ASCT proved to
be signiﬁcant with respect to PFS. Patients undergoing ASCT
while in ﬁrst CR had a longer 2-year PFS compared with
patients undergoing ASCT with any other disease status
(81.1% versus 55.6%, P¼ .041, Figure 1). No variablewas found
to be signiﬁcant with respect to OS (disease status could not
be evaluated as an endpoint because no deaths occurred in
patients receiving ASCT in ﬁrst CR). Multivariable analysis
was not performed because no other factorswere found to be
statistically signiﬁcant univariately.
Toxicity data were available for 57 of 63 patients. Aside
from 1 grade 3 pulmonary toxicity, the only grades 3 to 4
Table 1
Patient, Disease, and Transplant Characteristics
Variable Value
Patient gender
Female 24 (38)
Male 39 (62)
Median age at ASCT, yr (range) 59.5 (36.4-69.0)
Disease stage at ASCT
Stages 0-II 19
Stages III-IV 35
Not applicable 9
Lactate dehydrogenase at ASCT
 Normal range 42
> Normal range 20
No data 1
Median time from transformed DLBCL to ASCT,
mo (range)
7.5 (2.8-116.0)
Disease status from last therapy to ASCT
First CR 30 (48)
First PR 11 (17)
First relapse 14 (22)
Second CR 6 (9)
Second relapse 1 (2)
At least third CR 1 (2)
Chemosensitivity at ASCT
Resistant 2 (3)
Sensitive 61 (97)
Bone marrow involvement at ASCT
No 54 (86)
Yes 9 (14)
Number of prior regimens (range) 2 (1-6)
KPS score at ASCT (n ¼ 57) (range) 90 (70-100)
Treatment center
Chaim Sheba Medical Center 6 (9.5)
City of Hope Medical Center 20 (32)
University Medical Center Göttingen 6 (9.5)
VU University Medical Center 31 (49)
KPS indicates Karnofsky Performance Status.
Values are number of cases with percents in parentheses, unless otherwise
noted.
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toxicities reported were 14 infections. Notably, there was no
grade 3 stomatitis.
DISCUSSION
Transformation of low-grade lymphoma into an aggres-
sive lymphoma, usually DLBCL, has traditionally heralded a
poor prognosis with a median survival of 1 year after
transformation [3], with ASCT used to improve these results.
However, these statistics are derived from studies predating
the rituximab era, and more recent literature indicates that
outcomes have improved signiﬁcantly since the advent of
rituximab. For instance, Guirguis et al. [15] reported a cohort
of 317 DLBCL patients treated between 2002 and 2010
with R-CHOP (rituximab with cyclophosphamide, hydrox-
ydaunomycin, Oncovin, prednisone), including 60 patients
with transformed lymphoma who had never previously
received R-CHOP before transformation. They found no
difference in PFS or OS between patients with de novo or
transformed DLBCL when treated with R-CHOP alone.
Whether or not ASCT should be routinely performed for
transformed lymphoma has been called into question [16].
Interpretation of the available data is complicated by sig-
niﬁcant heterogeneity across studies with respect to clinical
variables such as treatment history before transformation,
regimens elected after transformation, rituximab use, and
disease status at the time of transplantation. A large series
from the Center for International Blood and Marrow Trans-
plant Research [17] reported 108 patients with transformed
follicular lymphoma treated with ASCT with a 5-year OS of
50% and 5-year PFS of 35%; however, only 30% of these pa-
tients had prior rituximab exposure. Nonetheless, 2 recent
cohort studies found beneﬁt from ASCT in patients with
transformed lymphoma [18,19]. A Canadian retrospective
study of 97 patients treated with autologous and 22 with
allogeneic transplant compared with 53 patients treated
with rituximab-containing chemotherapy found that ASCT
confers improved OS compared with rituximab-containing
chemotherapy, whereas allogeneic transplant does not [18].
One of the most common conditioning regimens for ASCT
in aggressive lymphoma is BEAM, and there has been interest
in combining it with radioimmunotherapy to improve on
outcomes. We previously showed Z-BEAM conditioning fol-
lowed by ASCT is feasible and does not add signiﬁcant
toxicity when compared with BEAM alone [11]. Further data
have shown a promising response rate and PFS of this
regimen in patients with both poor-risk de novo DLBCL [20]
and relapsed and refractory DLBCL [21], leading to interest in
testing this regimen speciﬁcally in patients with transformed
NHL. Here, we report a 2-year PFS of 68% and OS of 90% with
a median follow-up of over 2 years, results that compare
favorably with other series involving patients with trans-
formed lymphoma who received prior rituximab. Only the
disease status at the time of transplantation proved to be a
signiﬁcant predictor of outcome, with patients transplanted
while in ﬁrst CR having a signiﬁcantly improved PFS, pre-
sumably a marker for more chemosensitive disease. More-
over, both short- and long-term toxicities of this regimen
appear to be manageable in this group of patients. There was
no NRM, engraftment was not signiﬁcantly delayed, and no
patient experienced grade 3 mucositis, the latter an impor-
tant result in light of a recent phase III trial showing the
addition of iodine-131 tositumumab, another CD20-directed
radioimmunotherapy agent, to BEAM for ASCT conditioning
resulted in signiﬁcantly worse mucositis than did BEAM
alone [22]. Finally, albeit with limited follow-up, only 1 pa-
tient in this cohort developed a therapy-related myeloid
neoplasm.
Our study has the advantage that all patients received
rituximab in at least 1 of their regimens before transplant,
which makes the results more applicable to current practice.
In addition, histological proof of transformationwas required
rather than simply clinical features suggestive of trans-
formation. Limitations of the study include its retrospective
single-arm design with the inherent biases associated with
this type of analysis. To our knowledge this is the largest
series of transformed NHL patients treated with this novel
conditioning regimen. In summary, our data suggest that
excellent therapeutic efﬁcacy with acceptable toxicity are
conferred by the addition of yttrium-90 ibritumomab tiux-
etan to high-dose BEAM as a conditioning regimen for ASCT
in patients with transformed NHL.
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Figure 1. OS was deﬁned as time from date of stem cell infusion until death
from any cause. PFS was deﬁned as time from stem cell infusion until disease
relapse or progression or death from any cause, whichever came ﬁrst. Both OS
and PFS were calculated by the Kaplan-Meier method (A) OS and PFS of all
patients: solid line indicates OS survival curve and dashed line is PFS. Median
follow-up was 31.3 months (range, 7.1 to 103.4) for surviving patients (B) PFS
stratiﬁed by disease status: solid line indicates patients in ﬁrst CR (CR1) at
transplant and dashed line indicates patients beyond CR1. Median follow-up
for surviving patients was 25.5 months (range, 7.1 to 103.4) for patients in
CR1 and 38.0 months (range, 11.7 to 99.6) for patients beyond CR1.
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